Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.77 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | ITK | Q08881 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | MLLT1 | Q03111 | 4/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22453583 | 0.87 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL22445841 | 0.86 | LRRK2 (0.70) | LRRK2MAOBMAOAACHENPC1 | |
| SCHEMBL22445931 | 0.81 | MAOB (0.56) | LRRK2MAOBMAOAACHENPC1 | |
| SCHEMBL8251866 | 0.80 | JAK2 (0.74) | LRRK2ITKNPC1RAB9AAURKA | |
| SCHEMBL14514347 | 0.79 | ITK (0.67) | LRRK2ITKAURKAJAK2JAK1 | |
| SCHEMBL5379148 | 0.79 | JAK2 (0.65) | LRRK2ITKAURKAJAK2JAK1 | |
| SCHEMBL22445909 | 0.79 | LRRK2 (0.51) | LRRK2ITKAURKAJAK2JAK1 | |
| SCHEMBL29510910 | 0.78 | NPC1 (0.78) | LRRK2MAOBMAOAACHENPC1 | |
| SCHEMBL5377699 | 0.77 | AURKA (0.60) | LRRK2ITKAURKAJAK2JAK1 | |
| SCHEMBL8260093 | 0.77 | JAK2 (0.70) | LRRK2ITKAURKAJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | LRRK2 1/4885MAOB 1211/4885MAOA 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.